Similarly, research in cutaneous T-cell lymphoma has highlighted how the combination of Talazoparib and Romidepsin can induce Blimp–1–mediated p53-dependent apoptosis53. This evidence concerns the gene TP53 and primary cutaneous T-cell non-Hodgkin lymphoma.